Ironwood Pharmaceuticals Expands Pediatric Approval for Linzess
Ironwood Pharmaceuticals has received FDA approval to expand the use of its drug Linzess to treat functional constipation in children as young as two years old. This expansion strengthens Linzess's market position and treatment reach, making it the only FDA-approved medication for this condition in such a pediatric age group.
Tickers: $IRWD
Topics: approval expansion linzess pediatrics pharma